OPKO Biologics, a development stage biopharmaceutical company, is engaged in the development of proprietary versions of already-approved therapeutic proteins. Its technology, Carboxyl Terminal Peptide (CTP) is used to develop new and proprietary versions of existing therapeutic proteins that have longer life spans than therapeutic proteins without CTP. The company’s products under development include human growth hormone, which is used for the long-term treatment of children and adults with growth failure due to inadequate secretion of endogenous growth hormone; and factor IX that is offered to Hemophilia B patients to control blood clotting or coagulation. Its products under development also comprise anti-obesity peptide oxyntomodulin, factor VIIa, interferon ß and erythropoietin, and atherosclerosis and rheumatoid arthritis long-acting therapies. OPKO Biologics is based in Ness Ziona, Israel. Opko Biologics operates as a subsidiary of OPKO Health, Inc.